Workshop A Tuesday, July 16

8:00 am - 11:00 am

Challenges, Insights & Future Directions for Experimental Models in Cancer Immunotherapy

Workshop Leader: Shiva Kazerounian, Principal Scientist, In Vivo Pharmacology Lead , Berg Pharma


Understanding tumor placement, immune composition, response to treatment, and molecular characterization for the model of interest can be invaluable when designing the most appropriate study for your research goals. However, major issues remain, not only in selecting and optimizing models and tools for cancer immunotherapy research, but in selecting who to work with and when. Discussions in this session will centre on:
  • The range of current IO models available amongst their strengths and weaknesses
  • Mouse syngeneic models, their genetic backgrounds and use in IO for mono or combination therapy
  • How to identify, select and work with model developers and CRO’s available

Shiva Kazerounian, Principal Scientist, In Vivo Pharmacology Lead , Berg Pharma

Workshop B Tuesday, July 16

11:30 am - 2:30 pm

Introduction & Overview to 3D High Content Screening Approaches

Workshop Leader: Alejandro Amador, Head, Scientific Leader Discovery Biology Automation, GSK

3D high content approaches offer significant opportunity for improving cancer drug discovery. However, there exists formidable technical hurdles for HCS methods and analytical approaches. The session will look to explore the current start-of the art alongside the emergence of new technologies and techniques enabling 3D HCS applications. Discussions will centre on the marriage of 3D and high-content screening (HCS) to discover targeted cancer drug therapies

Leave having explored:

  • The value, impact and approaches for use of 3D-HCS within cancer discovery
  • 3D High-content analysis algorithm approaches for HCS
  • How multiparametric analyses can be incorporated to evaluate phenotypic compound effects

Alejandro Amador, Head, Scientific Leader Discovery Biology Automation, GSK

Workshop C Tuesday, July 16

3:00 pm - 6:00 pm

Considerations in Modelling the Microenvironment

Workshop Leader: Esmaiel Jabbari, Professor , University of South Carolina

In the last few decades, cancer stem cells (CSC) have proven to play a key role in tumor initiation resistance and recurrence. Recent advances have also begun to elucidate the complex cross talk at different stages of tumor progression between the TME and CSC’s. This session aims to provide an insight into the role and importance of CSC’s in the context of the ME as well as examine the clinical implications of targeting these interactions.

Topics to be covered include:

  • Current state of the art for modelling the TME interactions in the context of the CSC niche.
  • The importance of CSC TME interactions alongside potential therapeutic targets for the development of more effective treatments against cancer
  • The significance of stromal cells, immune cells, extracellular matrix, tumor stiffness, and hypoxia in regulation of CSC plasticity and therapeutic resistance

Esmaiel Jabbari, Professor , University of South Carolina